---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-23-000048"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2023-06-20T23:59:59+00:00"
generated_at: "2026-06-13T21:19:38.375034+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Recursion reports stockholder meeting results; all four proposals approved

## Summary
- Terry-Ann Burrell and Christopher Gibson elected Class II directors with 163.4M and 169.4M votes for.
- Advisory vote on executive compensation approved with 178.8M for (98.9% of votes cast).
- Stockholders favored an annual advisory vote on executive compensation (180.1M for 1 year).
- Ratification of Ernst & Young as independent auditor for FY 2023 approved with 210.6M for.

## SEC filing metadata
- accession: 0001601830-23-000048
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2023-06-20T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000048/0001601830-23-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000048/rxrx-20230616.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-23-000048
- JSON: https://secwatch.observer/filing/0001601830-23-000048.json
- Plain text: https://secwatch.observer/filing/0001601830-23-000048.txt

## Key facts
- Shareholder Votes
  RECURSION PHARMACEUTICALS, INC. shareholders approved Advisory resolution to approve executive compensation at the 2023-06-16 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast: For Against Abstain Broker Non-Votes 178,827,946 1,734,461 326,236 29,965,701
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000048/0001601830-23-000048-index.htm
- Shareholder Votes
  RECURSION PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for year ending December 31, 2023 at the 2023-06-16 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: Proposal 4: The appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2023 was ratified, with the following votes cast: For Against Abstain 210,585,521 71,005 197,818
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000048/0001601830-23-000048-index.htm
- Shareholder Votes
  RECURSION PHARMACEUTICALS, INC. shareholders approved Election of Terry-Ann Burrell as Class II director at the 2023-06-16 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: Proposal 1: The stockholders elected as Class II directors the two individuals listed below to serve until the Company’s 2026 annual meeting of stockholders, or until their respective successors are duly elected and qualified. The voting results were as follows: Nominee For Withheld Broker Non-Votes Terry-Ann Burrell, M.B.A. 163,422,186 17,466,457 29,965,701 Christopher Gibson, Ph.D. 169,410,560 11,478,083 29,965,701
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000048/0001601830-23-000048-index.htm
- Shareholder Votes
  RECURSION PHARMACEUTICALS, INC. shareholders approved Election of Christopher Gibson as Class II director at the 2023-06-16 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: Proposal 1: The stockholders elected as Class II directors the two individuals listed below to serve until the Company’s 2026 annual meeting of stockholders, or until their respective successors are duly elected and qualified. The voting results were as follows: Nominee For Withheld Broker Non-Votes Terry-Ann Burrell, M.B.A. 163,422,186 17,466,457 29,965,701 Christopher Gibson, Ph.D. 169,410,560 11,478,083 29,965,701
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000048/0001601830-23-000048-index.htm
- Shareholder Votes
  RECURSION PHARMACEUTICALS, INC. shareholders approved Advisory vote on the frequency of the advisory vote on executive compensation at the 2023-06-16 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: Proposal 3: The advisory vote on the frequency of the advisory vote on executive compensation favored an annual vote, with the following votes cast: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 180,126,697 17,141 598,617 146,188 29,965,701
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000048/0001601830-23-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.